Nasdaq · CIK 0001815442 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
KYMERA THERAPEUTICS, INC.
KYMR chart by TradingView
PRICE HISTORY
LIVE · NASDAQKYMR chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.0B
- EBITDA
- $-0.3B
- FREE CASH FLOW
- $-0.2B
- EPS
- $-3.69
- GROSS MARGIN
- 0.00%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 27 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
107.2x
+239%17.3x173.2x
⤢
P / BOOK
7.5x
+97%2.1x8.5x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
-2.11%
-9.5pp-21.38%7.35%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.1B
+6742%⤢
EBITDA (DERIVED)
$-0.1B
$0.1B⤢
NET INCOME
$-0.1B
$0.0B⤢
EPS (DILUTED)
$-0.62
+$0.11⤢
REVENUE GROWTH YOY
466.40%
+20.8pp-84.56%466.40%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
-83.90%
+308.5pp-2328.56%889.41%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
-19.85%
-4.8pp-42.34%-15.04%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN0.00%
OPERATING MARGIN-116.32%
NET MARGIN-94.17%
FCF MARGIN-83.90%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.1B
$0.0B⤢
STOCK-BASED COMP
$0.0B
+7993%⤢
CAPITAL EXPENDITURE
$0.0B
-66%⤢
SHARES OUTSTANDING
0.10B
+466%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.1B
+2231%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 115.69%INSIDERS 2.12%OTHER / RETAIL 0.00%375 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| FMR, LLC | 14.07% | 11.7M | $1.26B | +31.0% |
| Baker Bros. Advisors, LP | 10.41% | 8.7M | $930.8M | +0.0% |
| Avoro Capital Advisors LLC | 8.99% | 7.5M | $803.7M | +0.0% |
| Price (T.Rowe) Associates Inc | 7.29% | 6.1M | $651.7M | -1.6% |
| BVF Inc. | 6.62% | 5.5M | $591.7M | +0.0% |
| T. Rowe Price Investment Management, Inc. | 6.57% | 5.5M | $587.6M | +767.8% |
| Blackrock Inc. | 6.09% | 5.1M | $544.1M | +1.1% |
| Atlas Venture Life Science Advisors, LLC | 5.51% | 4.6M | $492.2M | -1.8% |
| Wellington Management Group, LLP | 4.68% | 3.9M | $418.2M | -11.9% |
| Siren, L.L.C. | 3.83% | 3.2M | $342.6M | -3.0% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.